Epizyme joins the queue of biotechs now hand­ing out pink slips, con­serv­ing cash

You can add Epizyme to the ros­ter of biotechs re­or­ga­niz­ing and down­siz­ing — in staff and R&D projects — in the face of a bru­tal bear mar­ket at­tack.

The biotech put out word to­day that it has brought out the ax to chop off 12% of its staff, with­out spec­i­fy­ing the num­bers. That should be good for ap­prox­i­mate­ly $3 mil­lion in cost re­duc­tions.

Epizyme is al­so shelv­ing two stud­ies: “Tazeme­to­stat in com­bi­na­tion with rit­ux­imab (SYM­PHO­NY-2, EZH-1401), as well as its Phase 1/1b bas­ket study eval­u­at­ing tazeme­to­stat com­bi­na­tions in pa­tients with sol­id tu­mors (EZH-1301),” reads the lat­est busi­ness up­date to­day cov­er­ing 2021 re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER